HIV-Associated Lung Cancer

Kiderlen, Til R.; Siehl, Jan; Hentrich, Marcus

doi:10.1159/000458442

Cited by 15 publications

(14 citation statements)

References 66 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The advent of ART has improved survival of HIV-infected adults and children leading to chronic illnesses such as different pulmonary diseases [ 7 , 8 ]. For instance, chronic obstructive pulmonary disease (COPD), asthma, pulmonary hypertension, lung cancer, and asthma are prevalent among HIV patients [ 7 , 9 , 10 , 11 , 12 , 13 ].…”

Section: Introductionmentioning

confidence: 99%

HIV gp120 Induces the Release of Proinflammatory, Angiogenic, and Lymphangiogenic Factors from Human Lung Mast Cells

et al. 2020

View full text Add to dashboard Cite

Human lung mast cells (HLMCs) express the high-affinity receptor FcεRI for IgE and are involved in chronic pulmonary diseases occurring at high frequency among HIV-infected individuals. Immunoglobulin superantigens bind to the variable regions of either the heavy or light chain of immunoglobulins (Igs). Glycoprotein 120 (gp120) of HIV-1 is a typical immunoglobulin superantigen interacting with the heavy chain, variable 3 (VH3) region of human Igs. The present study investigated whether immunoglobulin superantigen gp120 caused the release of different classes of proinflammatory and immunoregulatory mediators from HLMCs. The results show that gp120 from different clades induced the rapid (30 min) release of preformed mediators (histamine and tryptase) from HLMCs. gp120 also caused the de novo synthesis of cysteinyl leukotriene C4 (LTC4) and prostaglandin D2 (PGD2) from HLMCs. Incubation (6 h) of HLMC with gp120 induced the release of angiogenic (VEGF-A) and lymphangiogenic (VEGF-C) factors from HLMCs. The activating property of gp120 was mediated through the interaction with IgE VH3+ bound to FcεRI. Our data indicate that HIV gp120 is a viral superantigen, which induces the release of different proinflammatory, angiogenic, and lymphangiogenic factors from HLMCs. These observations could contribute to understanding, at least in part, the pathophysiology of chronic pulmonary diseases in HIV-infected individuals.

show abstract

Section: Introductionmentioning

confidence: 99%

HIV gp120 Induces the Release of Proinflammatory, Angiogenic, and Lymphangiogenic Factors from Human Lung Mast Cells

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Through the literature search in PubMed and Embase databases, we found a total of 923 individual records, but only 22 studies were considered possibly eligible and were evaluated by reading the full articles. [ 7 , 23 , 27 – 34 , 41 – 52 ] Ten studies were excluded because they did not assess the impact of HIV infection on the survival of lung cancer patients or they did not report data on the estimates of mortality risk associated with HIV infection. [ 7 , 23 , 45 – 52 ] At last, 12 studies were included into the meta-analysis.…”

Section: Resultsmentioning

confidence: 99%

Human immunodeficiency virus infection and mortality risk among lung cancer patients

Wang

Shen

2018

Medicine

View full text Add to dashboard Cite

Background:Previous studies have suggested that patients with human immunodeficiency virus (HIV) infection are at higher risk of lung cancer, but the impact of HIV infection on the risk of mortality among lung cancer patients is still unclear. We conducted a systematic review and meta-analysis to clarify the association between HIV infection and mortality risk among lung cancer patients.Methods:PubMed and Embase databases were searched to identify studies assessing the association between HIV infection and mortality risk among lung cancer patients. Only studies reporting adjusted relative risk (RR) of mortality among lung cancer patients with HIV infection were included. Meta-analysis of random-effect model was utilized to calculate the pooled RR with 95% confidence interval (CI).Results:Twelve cohort studies were finally included. Compared with lung cancer patients without HIV infection, the pooled RR of mortality among lung cancer patients with HIV infection was 1.48 (95% CI, 1.22–1.78, P < .001; I2 = 88.6%). After excluding 2 studies with low quality, HIV infection was still significantly associated with an elevated risk of mortality among lung cancer patients (RR = 1.51, 95% CI, 1.25–1.82, P < .001; I2 = 89.8%). Sensitivity analysis showed that the statistical significance of the pooled RR was not changed by excluding any one study.Conclusion:The outcomes from the meta-analysis provide strong evidence for the elevated risk of mortality among lung cancer patients with HIV infection, and HIV infection is an important prognostic factor in lung cancer patients.

show abstract

“…HIV-infection status seems not to correlate with histotype and disease stage of LC [29,30] and, while controversial data in this regard have been reported [31], even more recent large cohort studies confirmed that distributions of the cancer stage at presentation and histologic subtypes are similar by HIV status [32,33].…”

Section: Lung Cancer Features In Hiv Infected Patientsmentioning

confidence: 94%

Lung Cancer (LC) in HIV Positive Patients: Pathogenic Features and Implications for Treatment

Frega

Ferro

Bonanno

et al. 2020

IJMS

View full text Add to dashboard Cite

The human immunodeficiency virus (HIV) infection continues to be a social and public health problem. Thanks to more and more effective antiretroviral therapy (ART), nowadays HIV-positive patients live longer, thus increasing their probability to acquire other diseases, malignancies primarily. Senescence along with immune-system impairment, HIV-related habits and other oncogenic virus co-infections increase the cancer risk of people living with HIV (PLWH); in the next future non-AIDS-defining cancers will prevail, lung cancer (LC) in particular. Tumor in PLWH might own peculiar predictive and/or prognostic features, and antineoplastic agents’ activity might be subverted by drug-drug interactions (DDIs) due to concurrent ART. Moreover, PLWH immune properties and comorbidities might influence both the response and tolerability of oncologic treatments. The therapeutic algorithm of LC, rapidly and continuously changed in the last years, should be fitted in the context of a special patient population like PLWH. This is quite challenging, also because HIV-positive patients have been often excluded from participation to clinical trials, so that levels of evidence about systemic treatments are lower than evidence in HIV-uninfected individuals. With this review, we depicted the epidemiology, pathogenesis, clinical-pathological characteristics and implications for LC care in PLWH, offering a valid focus about this topic to clinicians.

show abstract

HIV-Associated Lung Cancer

Cited by 15 publications

References 66 publications

HIV gp120 Induces the Release of Proinflammatory, Angiogenic, and Lymphangiogenic Factors from Human Lung Mast Cells

HIV gp120 Induces the Release of Proinflammatory, Angiogenic, and Lymphangiogenic Factors from Human Lung Mast Cells

Human immunodeficiency virus infection and mortality risk among lung cancer patients

Lung Cancer (LC) in HIV Positive Patients: Pathogenic Features and Implications for Treatment

Contact Info

Product

Resources

About